Recent content by RTMcFadden

Novitzky works for Dr. Margaret Hamburg.

Thought your name seemed familiar. I do believe we've done business in the past. If so, I can attest to the fact that his kung fu is strong.

As in, say, reasearch. Actually, this methodology can be used at three different points in the method life cycle: development, improvement, and validation. Like samples that have already been tested and deemed to be negative. It's nice to see that after all of these years people have...

There are no active clinical trials that I'm aware of, because all of the patients tend to die. While this is and has been a hot area of research, they haven't been able to translate it into somehting useful at this point.

Actually, Sudafed is manufactured and distributed by McNeil Consumer Products Co., a division of Johnson & Johnson.

It very much comports with the facts in that they suspended him from Italian events.

Exactly. The Testosterone level was borderline low, and the Epitestosterone level was almost undetectable. A simple understanding of mathematics will tell you that based upon the absolute numbers, any meaning derived from the ratio should be treated with skepticism.

I highly doubt that. If I have time today, I'll look into it.

Joe Papp posted a notice about this test over a year ago. I don't know how rugged the test method is, but it should be fairly sensitive to detect the plasticizers because they would be in failry low concentrations.

Can speak for him, but I can speak for myself. EPO was first commerically produced in 1986.

This is where I have a problem. Given that WADA Technical Document TD2009EPO, version 2.0, effective Sept. 21, 2009, and TD2004EPO, effective Jan. 15, 2005 section 3.3 and page 5 Stability Criteria, respectively, specify the addition of BPR or NESP at 1.5x the concentration used in the...

Actually, spiking a sample would be a fairly simple task.

Below is an article that explains why gene therapy as treatment vector kind of died out. This occurred in 2000 and caused everyone to go back to the drawing board. http://www.thelabrat.com/review/genetherapydeath.shtml Below is an article indicating that gene therapy is coming back into...

Their need to be the big fish is so over-riding that they go in search of a smaller pond. That's so funny. Pathetic, but funny.

Not sure if Sarbanes-Oxley Section 806 itself applies. There is a patchwork of wistle-blower regulations of which SOX 806 is a part. I suspect that any protection would come from one of the other areas, if there is any. Of course, this is just speculation on my part.